Figure 1: Top 10 Selling Products of Aztrazeneca (US$ mill)

Source: GlobalData, Pharma Intelligence Center, [Accessed 19th Dec 2017]

Figure 1 displays the sales values of the top ten products of AstraZeneca for 2016. Crestor, Symbicort, and Nexium are the best performing drugs by a large margin, however, with many of their exclusivities expiring; revenues for these drugs are expected to half by 2023. This will leave a potential gap in AstraZeneca’s profits that they will hope to fill with their non-small cell lung cancer drug Tagrisso. The rest of these drugs are expected to remain a relatively constant source of income, with the exceptions being Forxiga and Seroquel IR/XR. Forxiga expecting to grow into the 2,000’s (US$m), and Seroquel expecting to crash into the 100’s (US$m) by 2023.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.